Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study

INTRODUCTION: Atopic dermatitis (AD) is a chronic inflammatory skin disorder with limited treatment options for adolescents with moderate-to-severe disease. Lebrikizumab, a monoclonal antibody targeting interleukin (IL)-13, demonstrated clinical benefit in previous Phase 3 trials: ADvocate1 (NCT0414...

Descripción completa

Detalles Bibliográficos
Autores principales: Paller, Amy S., Flohr, Carsten, Eichenfield, Lawrence F., Irvine, Alan D., Weisman, Jamie, Soung, Jennifer, Pinto Correia, Ana, Natalie, Chitra R., Rodriguez Capriles, Claudia, Pierce, Evangeline, Reifeis, Sarah, Gontijo Lima, Renata, Armengol Tubau, Clara, Laquer, Vivian, Weidinger, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307734/
https://www.ncbi.nlm.nih.gov/pubmed/37318750
http://dx.doi.org/10.1007/s13555-023-00942-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307734/
https://www.ncbi.nlm.nih.gov/pubmed/37318750
http://dx.doi.org/10.1007/s13555-023-00942-y

Ejemplares similares